ProCE Banner Activity

CA209-040: Nivolumab With Promising Safety and Antitumor Activity in Advanced HCC

Slideset Download
Conference Coverage
Results of a phase1/2 study of nivolumab monotherapy in patients with advanced hepatocellular carcinoma reveal encouraging 12 month survival rate

Released: May 31, 2015

Expiration: May 29, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation